Horm Metab Res 1998; 30(4): 227-229
DOI: 10.1055/s-2007-978871
Originals Clinical

© Georg Thieme Verlag Stuttgart · New York

Allopregnanolone in Women with Premenstrual Syndrome

M. Bičíková1 , L. Dibbelt2 , M. Hiill1 , R. Hampl1 , L. Stárka1
  • 1Institute of Endocrinology, Praha, Czech Republic
  • 2Institut für Klinische Chemie, Lübeck, Germany
Further Information

Publication History

1997

1997

Publication Date:
20 April 2007 (online)

5α-reduced metabolites of progesterone, especially 3α-hydroxy-5α-pregnan-20-one (allopregnanolone) are now listed to neurosteroids. Their anesthetic properties can be explained by their allosteric interaction with GABAA receptors. A woman's organism is provided with an abundance of progesterone during the luteal phase of the menstrual cycle and its level falls down sharply with the first day of menses. The level of allopregnanolone follows that of progesterone. Many women suffer from so called premenstrual syndrome (PMS) during the luteal phase. In this study we have determined allopregnanolone and progesterone levels and their ratios in order to assess the over-all activity of C21-steroid 5α-reductase in these patients and in controls. Significantly lower levels of both progesterone and allopregnanolone than in controls have been found in PMS patients in the follicular phase only.

    >